CYTOMEGALOVIRUS PP65 ANTIGEN-GUIDED PREEMPTIVE THERAPY WITH GANCICLOVIR IN SOLID ORGAN TRANSPLANT RECIPIENTS: A PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
- 1 October 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 72 (7) , 1325-1327
- https://doi.org/10.1097/00007890-200110150-00025
Abstract
The aim of this study was to evaluate pp65 antigen-guided antiviral therapy in preventing human cytomegalovirus (HCMV) infection in solid organ transplant recipients. Ten kidney and two liver transplant recipients with asymptomatic HCMV infection were randomized either for i.v. ganciclovir or placebo treatment in a prospective, double-blind study. All patients were positive by HCMV pp65 antigen test at levels >5 positive cells/2×105 investigated cells. No cases of HCMV end-organ disease occurred. In contrast to patients on placebo (5/7), none of the patients on ganciclovir (0/5) developed HCMV-associated symptoms (P =0.01). However, because of the small number of patients, all three high-risk patients (donor seropositive, recipient seronegative) were randomized to placebo and all three developed symptoms. Preemptive antiviral therapy guided by the pp65 antigen test seems to have a beneficial effect on preventing HCMV-associated symptoms in kidney and liver transplant recipients.Keywords
This publication has 9 references indexed in Scilit:
- Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplantsThe Lancet, 2000
- CYTOMEGALOVIRUS PP65 ANTIGENEMIA MONITORING AS A GUIDE FOR PREEMPTIVE THERAPY: A COST EFFECTIVE STRATEGY FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN ADULT LIVER TRANSPLANT RECIPIENTS1Transplantation, 1999
- PROPHYLACTIC ORAL GANCICLOVIR COMPARED WITH DEFERRED THERAPY FOR CONTROL OF CYTOMEGALOVIRUS IN RENAL TRANSPLANT RECIPIENTS1,2,???Transplantation, 1997
- Prophylaxis against CMV infection in transplant patientsJournal of Antimicrobial Chemotherapy, 1997
- Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy.Journal of the American Society of Nephrology, 1997
- CYTOMEGALOVIRUS PROPHYLAXIS IN SOLID ORGAN TRANSPLANT RECIPIENTSTransplantation, 1996
- Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantationBlood, 1995
- Laboratory diagnosis of HCMV-related disease in renal transplant patients - pp65 antigen detection versus nested PCRClinical and Diagnostic Virology, 1995
- Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantationBlood, 1992